17 completed, 6 recruiting, 5 terminated, 5 unknown. 9 Not applicable, 8 Phase 2, 6 Phase 1, 3 Phase 3.
Follow Splenomegaly: new trials by email Literature Review of Splenomegaly trials Research Report on Splenomegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer TheraSphere - Gastrointestinal Cancer | Not applicable | Not yet recruiting | Centre Georges Francois Leclerc | 18 | 2026-10-01 | 2026-05-13 |
| Therapeutic RSK1 Targeting in Myeloid Malignancies PMD-026 - Myeloid Malignancy | Phase 1 | Recruiting | Washington University School of Medicine | 30 | 2026-05-20 | 2026-10-21 |
| Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies Primary Immune Deficiencies, Benign Lymphoproliferative Disorder | Not yet recruiting | Central Hospital, Nancy, France | 60 | 2026-04-01 | 2026-04-13 | |
| Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease Blood sampling for dosage - Splenomegaly, Splenectomy | Not applicable | Recruiting | Wladimir MAUHIN, Dr | 200 | 2025-06-05 | 2026-10-15 |
| High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam - Splenomegaly, Myelofibrosis | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-10-01 | 2026-09-16 |
| GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma Gaucher Disease, Acid SphingoMyelinase Deficiency | Recruiting | Fundación Española de Hematología y Hemoterapía | 210 | 2023-05-30 | 2026-02-11 | |
| PREDIGA 2: Spanish Acronym of "Educational and Diagnostic Project for Gaucher and ASMD" Patient with splenomegaly or splenectomy - Gaucher Disease, Acid SphingoMyelinase Deficiency | Completed | Fundación Española de Hematología y Hemoterapía | 122 | 2023-03-21 | 2026-02-19 | |
| A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen Gaucher Disease, Splenomegaly, Acid SphingoMyelinase Deficiency | Completed | Sanofi | 60 | 2021-06-30 | 2025-09-23 | |
| Ultrasound Guided Microwave Ablation of Splenomegaly in Children Microwave ablation - Splenomegaly; Congestive, Chronic, Panhematopenia; Splenic | Not applicable | Unknown | Karolinska Institutet | 10 | 2021-03-01 | 2022-01-04 |
| Incentive Spirometry and Upper Abdominal Laparoscopic Surgery Volume-oriented incentive spirometry, Flow-oriented incentive spirometry - Cholecystitis, Perforated Duodenal Ulcer | Not applicable | Completed | Riphah International University | 60 | 2020-10-01 | 2021-10-20 |
| Early Diagnosis of Oxaliplatin-induced Portal Hypertension the level of vWF - Gastroesophageal Varices, Colorectal Cancer | Unknown | Shanghai Zhongshan Hospital | 370 | 2020-08-31 | 2020-08-28 | |
| Oxaliplatin-induced Portal Hypertension Individualized Treatment - Gastroesophageal Varices Hemorrhage, Colorectal Cancer | Not applicable | Unknown | Shanghai Zhongshan Hospital | 25 | 2020-08-31 | 2020-08-24 |
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Ruxolitinib - BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells | Phase 2 | Active not recruiting | Stanford University | 8 | 2019-11-15 | 2026-09-01 |
| MPN-RC 118 AVID200 in Myelofibrosis AVID200 - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 1 | Completed | John Mascarenhas | 21 | 2019-02-15 | 2023-02-10 |
| Biomarker for Gaucher Disease: BioGaucher (BioGaucher) Splenomegaly, Hepatomegaly | Withdrawn | CENTOGENE GmbH Rostock | 2018-08-20 | 2023-02-13 | ||
| Biomarker for Farber Disease (BioFarber) Farber's Lipogranulomatosis, Ceramidase Deficiency | Withdrawn | CENTOGENE GmbH Rostock | 2018-08-20 | 2023-02-13 | ||
| Biomarker for Sly Disease (MPS VII) (BioSly) Developmental Delay, Skeletal Abnormalities | Withdrawn | CENTOGENE GmbH Rostock | 2018-08-20 | 2023-02-13 | ||
| A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis Ruxolitinib, Navitoclax - Myelofibrosis (MF) | Phase 2 | Completed | AbbVie | 191 | 2017-10-31 | 2026-01-20 |
| Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study - Anemia, Fatigue | Phase 1 | Completed | City of Hope Medical Center | 3 | 2017-09-07 | 2026-10-19 |
| Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Rigosertib, Questionnaire - Leukemia, Myelofibrosis | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2017-08-16 | 2020-08-07 |
Showing 20 of 41. Sign in to see all of them.
Primary Myelofibrosis (9) · Anemia (7) · Gaucher Disease (6) · Hepatomegaly (6) · Lymphadenopathy (5) · Thrombocytopenia (5) · Bone Marrow Diseases (4) · Hematologic Diseases (4) · Hypertension, Portal (4) · Niemann-Pick Diseases (4) · Autoimmune Lymphoproliferative Syndrome (3) · Fever (3) · Myeloproliferative Disorders (3) · Polycythemia Vera (3)
Hypertrophy (41) · Pathological Conditions, Anatomical (41) · Pathological Conditions, Signs and Symptoms (41) · Hemic and Lymphatic Diseases (24) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16) · Genetic Diseases, Inborn (15) · Digestive System Diseases (13) · Hematologic Diseases (12) · Neoplasms (12) · Lymphatic Diseases (11) · Liver Diseases (10) · Immune System Diseases (9) · Metabolic Diseases (9) · Metabolism, Inborn Errors (9) · Neoplasms by Site (9)
ruxolitinib (5) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (3) · Blood Specimen Collection (2) · Pyrimethamine (2) · Surveys and Questionnaires (2) · Adrenal Cortex Hormones (1) · Busulfan (1) · Cyclophosphamide (1) · Danazol (1) · Hydroxyurea (1) · Lenalidomide (1) · Levetiracetam (1) · Mesna (1) · Metformin (1) · Nivolumab (1)
M.D. Anderson Cancer Center (4) · CENTOGENE GmbH Rostock (3) · CTI BioPharma (2) · Fundación Española de Hematología y Hemoterapía (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Sanofi (2) · Shanghai Zhongshan Hospital (2) · University of British Columbia (2) · AbbVie (1) · Brigham and Women's Hospital (1) · Central Hospital, Nancy, France (1) · Centre Georges Francois Leclerc (1) · City of Hope Medical Center (1) · Istanbul University (1) · Jewish General Hospital (1)
United States (20) · France (7) · Canada (6) · Germany (5) · Australia (4) · Hungary (4) · India (4) · Israel (4) · Italy (4) · Spain (4) · United Kingdom (4) · China (3) · Czechia (3) · Russia (3) · Belgium (2)
Peter Bauer, Prof. (3) · Graydon S Meneilly, MD (2) · Simran Singh (2) · Abeer Fatima, MSPT-CPPT (1) · Amy W Zhou, M.D. (1) · Benjamin D Solomon, M.D. (1) · Beth Ziemba (1) · John Mascarenhas, MD (1) · Jorge Cortes, MD (1) · Koneti Rao, MD (1) · Loretta J Nastoupil (1)
PMID 17075116, PMID 32380558, PMID 33275766, PMID 18779617, PMID 25387438, PMID 28876454, PMID 33232476, PMID 34551507, PMID 35180010, PMID 35576960, PMID 39400386, PMID 40454409, PMID 40481534, PMID 40517417, PMID 40643151, PMID 41846295, PMID 42316774, PMID 42842696
2017 (1), P01CA108671 (1), P30CA016672 (1)